RE:$2.30 target priceSaw that this morning too. Conservative estimates with upside potential from growth drivers-
Launch of Pennsaid 2% with partners in new markets of India and Switzerland in
4Q-2020 (topical diclofenac market in both countries ~$35 MM);
• Potential approval of Pennsaid 2% in Austria, Greece, Italy and Portugal (markets
where Pennsaid 1.5% has already been approved) in 2020;
• Canadian launch of Suvexx in 3Q-2020. Product will compete in the $130 MM acute
migraine market - same market as Cambia (Suvexx for more severe patients);
• Potential approvals of line extensions of NeoVisc in 2Q-2020;
• Filing in 2Q-2020 for pediatric formulations of Blexten (decision in mid-2021);
• Resultz launch in Germany in 2Q-2020 with partner, Heumann (Germany is the
largest lice treatment market in Europe at 50 M euros);
• Finalize partnership for Resultz in the U.S. in time for the lice season this year.